| Symbol | ADIL |
|---|---|
| Name | ADIAL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA 22901 |
| Telephone | 434-422-9800 |
| Fax | — |
| — | |
| Website | https://www.adialpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001513525 |
| Description | Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Additional info from NASDAQ: |
New Form S-3 - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001213900-26-095122 <b>Size:</b> 710 KB
Read moreNew Form S-8 - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001213900-26-095119 <b>Size:</b> 405 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more(99% Neutral) ADIAL PHARMACEUTICALS, INC. (ADIL) Announces Regulatory Update
Read moreAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Read moreAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form ARS - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-24 <b>AccNo:</b> 0001213900-26-093022 <b>Size:</b> 1 MB
Read more(99% Neutral) ADIAL PHARMACEUTICALS, INC. (ADIL) Reports Q3 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04101227 | Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected S… | Phase3 | Alcohol Use Disorder | Completed | 2020-02-01 | 2022-03-18 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Brief Psychological Counseling | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| Companion Diagnostic for Genetic Testing | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| Matching placebo | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| AD04 (ondansetron) | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| ADS-8902 | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00979251 |
| Oseltamivir Phosphate | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00979251 |
| ADS-5102 (extended release amantadine HCl) | DRUG | Phase PHASE2 | Dyskinesia | COMPLETED | NCT01397422 |
| ADS-5102 | DRUG | Phase PHASE2 | Walking Impairment | COMPLETED | NCT02471222 |
| ADS-5102, 274 mg | DRUG | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT03567057 |
| 320mg Amantadine HCl ER tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| Placebo tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| 240mg Amantadine HCl ER tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| Placebo | OTHER | Phase PHASE2 | Walking Impairment | COMPLETED | NCT02471222 |
| amantadine HCl ER | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153632 |
| GOCOVRI | DRUG | Phase PHASE4 | Parkinson Disease | COMPLETED | NCT04387773 |